Advanced Antimicrobial Stewardship Curriculum Self-Study
The IDSA Advanced Antimicrobial Stewardship (AS) curriculum provides you with the knowledge and skills to become a leader in antimicrobial stewardship and is intended for those who are considering or actively pursuing a career in antimicrobial stewardship. It builds upon the IDSA CORE AS Curriculum, which provides fellows with a broad foundation in antimicrobial stewardship.
As with the CORE curriculum, the Advanced curriculum is designed for use at your home institution and builds on local AS resources. The content is organized into 5 main sections and includes eLearning modules, workbooks, and application activities.
Target Audience
Infectious Disease professionals who desire to lead an antimicrobial stewardship but are not in a participating fellowship program, no longer in fellowship, or generally would like to gain more knowledge on the subject.
Learning Objectives
Upon completion of this section, you will be able to:
- Develop a comprehensive antimicrobial stewardship program by defining overall goals, optimizing team structure, and carrying out regulatory and reporting aspects of stewardship
- Analyze local microbiology and antimicrobial data and use it to identify and implement impactful antimicrobial stewardship initiatives
- Apply behavioral psychology principles and leverage business principles to increase resources for antimicrobial stewardship and influence culture change by creating effective programmatic antimicrobial stewardship communication approaches
- Evaluate and plan the most effective diagnostic and antibiotic stewardship interventions for unique populations and settings (specifically the emergency department, immunocompromised populations, long-term care facilities, and outpatient sites)
- Identify resources for professional development in antimicrobial stewardship to be able to begin a career in antimicrobial stewardship
- Develop a plan to expand the reach of a stewardship program into the outpatient setting and effectively collaborate with OPAT programs to optimize stewardship efforts
NOTE: Because this curriculum was initially designed specifically for fellows, you may hear repeated reference to "fellows" ,"stewards in training" or "fellows/trainees"
Advanced AS Curriculum Workgroup COI Summary Reviewed April 2017 by Rachel Simmons, MD No conflicts found.
All relevant financial relationships have been mitigated.
Name | Individual's role in activity | Name of commercial interest | Nature of Relationship |
---|---|---|---|
Advani, Sonali | Workgroup Member | None | |
Armstrong, Wendy | Workgroup Member | None | |
Barsoumian, Alice | Workgroup Member | None | |
Beeler, Cole | Workgroup Member | None | |
Bennani, Kenza | Staff | None | |
Blair, Barbra | Workgroup Member | None | |
Brennan - Krohn, Thea | Workgroup Member | None | |
Bryson - Cahn, Chloe | Workgroup Member | None | |
Cherabuddi, Kartik | Workgroup Member | None | |
Fong, Gary | Workgroup Member | Critical Innovations, LLC | Advisory/Consultant Role |
Gaston, David | Workgroup Member | None | |
Hamilton, Keith | Workgroup Member | None | |
Holubar, Marisa | Workgroup Member | None | |
Huang, Misha | Workgroup Member | None | |
Ince, Dilek | Workgroup Member | Gilead Science’s Clinical Studies for remdesivir | Principal Investigator |
Accelerate Diagnostics | Research Grants/Contracts | ||
Leidos | Research Grants/Contracts | ||
Justo, Julie Ann | Workgroup Member | bioMerieux | Other remuneration - Speaker's Bureau |
Merck | Advisory/Consultant Role | ||
Vaxart | Stocks/Bonds | ||
Kang, Amy | Workgroup Member | None | |
Larnard, Jeff | Workgroup Member | None | |
Lee, Matthew | Workgroup Member | None | |
Logan, Ashleigh | Staff | None | |
Luther, Vera | Workgroup Member | None | |
MacDougal, Conan | Workgroup Member | None | |
Melia, Michael | Workgroup Member | Merck | Organizational Benefit |
Allergan | Organizational Benefit | ||
Pfizer; Melinta | Organizational Benefit | ||
Miller, Matt | Workgroup Member | Abbvie | Honoraria |
La Jolla | Honoraria | ||
Merck | Research Grant/Contract | ||
Moenster, Ryan | Workgroup Member | Shionogi | Advisory/Consultant Role, Honoraria |
Abbvie/Allergan | Advisory/Consultant Role, Honoraria | ||
Melinta Therapeutics | Advisory/Consultant Role, Honoraria | ||
Merck | Advisory/Consultant Role, Honoraria | ||
Nori, Priya | Workgroup Member | Merck | Co-infections in COVID-19 patients |
Paras, Molly | Workgroup Member | None | |
Patel, Payal | Workgroup Member | None | |
Rodvold, Keith | Workgroup Member | BLC USA LP | Advisory/Consultant Role, Honoraria |
VenatoRx | Advisory/Consultant Role, Honoraria | ||
Medicine Company/Qpex Biopharma | Advisory/Consultant Role, Honoraria | ||
Vemco Med Ed. (Merck CME/CPE programs) | Advisory/Consultant Role, Honoraria | ||
Debipharm | Advisory/Consultant Role, Honoraria | ||
Shionogi | Advisory/Consultant Role, Honoraria | ||
Unrestricted education grant for CME/CPE Program | |||
Utility Therapeutics | Advisory/Consultant Role, Honoraria | ||
Janssen | Data Safety Monitoring Board (DSMB) | ||
Clinartis LLC (projects associated with Spero Therapeutics and Sinovent) | Advisory/Consultant Role, Honoraria | ||
USCAST : US Ctte on Antimicrobial Susceptibility Testing | Voting Committee Member | ||
Schooneveld, Trevor | Workgroup Member | Rebiotix, Merk | Research Grant |
Thermo - Fischer | Speaking | ||
Schwartz, Brian | Workgroup Member | None | |
Spicer, Jennifer | Workgroup Member | None | |
Stack, Conor | Workgroup Member | None | |
Stead, Wendy | Workgroup Member | None | |
Stohs, Erica | Workgroup Member | Reviral Ltd | Research Grant |
Wiley, Zanthia | Workgroup Member | None | |
Willis, Zachary | Workgroup Member | None | |
Shnekendorf, Rachel | Staff | None | |
Vaezi, Liza | Workgroup Member | None | |
Rachel Simmons | Reviewer | None |
Accreditation Statement
In support of improving patient care, IDSA is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME Credit Designation Statement
IDSA designates this enduring material for a maximum of 18 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Physician participation information will be shared with ABIM through ACCME PARS.
CPE Accreditation Statement for Pharmacists
IDSA is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. ACPE Universal Activity Number (JA0007082-0000-21-003-H04-P) has been assigned to this knowledge-based activity. This activity is acceptable for a maximum of 18 on-demand CPE contact hours (1.8 CEUs) in states that recognize ACPE providers.
Upon completion of this ACPE-approved activity, participants will receive 18 credits that will be automatically uploaded to their NABP e-Profile section of the CPE Monitor. It is the participant's responsibility to upload the correct NABP number to their profile.
Available Credit
- 18.00 ABIM MOC II
- 18.00 ACPE Pharmacy
- 18.00 AMA PRA Category 1 Credit(s)™